期刊文献+

琥珀酸美托洛尔缓释片联合氯沙坦钾片治疗老年慢性心力衰竭的效果分析 被引量:1

下载PDF
导出
摘要 目的:观察琥珀酸美托洛尔缓释片联合氯沙坦钾片治疗老年慢性心力衰竭患者的治疗疗效,探究二者结合的安全性和耐受性,为临床医学提供治疗经验经验,帮助患者早日恢复身体健康。方法:选取我院自2015年12月~2016年12月确诊为老年慢性心力衰竭的患者资料72例,将这72例患者平均分为两组,每组人数均为36例,并分别命名为观察组与对照组。对照组的患者采用绿沙坦钾片治疗,观察则在对照组常规治疗以及使用氯沙坦钾片治疗的基础上使用琥珀酸美托洛尔缓释片进行治疗。一段时间的治疗结束之后,观察两组患者治疗前后的身体反映情况,记录其不良反应和身体指标的相关数据,根据有关数据进行结果分析。结果:一段时间的治疗结束之后,显示。两组患者的患者身体治疗前后情况相差较大,最终观察组的总治疗总有效率为97.2%,而对照组治疗的总有效率则为75.0%。差异具有统计学意义(p<0.01)。结论:采用琥珀酸美托洛尔缓释片联合氯沙坦钾片的方式治疗老年慢性心力衰竭患者具有良好的治疗疗效以及高安全性及耐受性,建议临床上广泛使用,帮助患者脱离疾病的困扰。
作者 刘宗侠
出处 《中国农村卫生》 2018年第8期15-15,21,共2页
  • 相关文献

参考文献2

二级参考文献20

  • 1夏华玲,李迎春,黄中云.缬沙坦治疗慢性心力衰竭疗效观察[J].临床医学,2006,26(3):36-37. 被引量:13
  • 2[1]Macdonald PS,Hill J,Krum H.COLA Ⅱ Investigators.The impact of baseline HR and BP on the tolerability of carvedilol in the elderly:the COLA (Carvedilol Open Label Assessment) Ⅱ Study[J].Am J Cardiovasc Drugs,2006,6(6):401-405.
  • 3[2]Dobre D,van Veldhuisen DJ.SENIORS Investigators.Tolerability and dose-related effects of nebivolol in elderly patients with heart failure:data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial[J].Am Heart J,2007,154 (1):109-115.
  • 4[3]Willenheimer R,van Veldhuisen DJ,CIBIS Ⅲ Investigators.Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril,as compared with the opposite sequence:results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) Ⅲ.Circulation,2005,112(16):2426-2435.
  • 5[4]Chuen M J,MacFadyen RJ.Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure[J].Am J Cardiol,2006,98(10):1416-1417.
  • 6[5]Gheorghiade M,Konstam MA,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Shortterm clinical effects of tolvaptan,an oral vasopressin antagonist,in patients hospitalized for heart failure:the EVEREST Clinical Status Trials[J].JAMA,2007,297 (12):1332-1343.
  • 7[6]Konstam MA,Gheorghiade M,Burnett JC Jr,et al.Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators.Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial[J].JAMA,2007,297(12):1319-1331.
  • 8[7]Cleland JG,Coletta AP,Clark AL.Clinical trials update from the American College of Cardiology 2007:ALPHA,EVEREST,FUSION Ⅱ,VALIDD,PARR-2,REMODEL,SPICE,COURAGE,COACH,REMADHE,pro-BNP for the evaluation of dyspnoea and THIS-diet[J].Eur J Heart Fail,2007,9(6-7):740-745.
  • 9[8]Go AS,Lee WY,Yang J,et al.Statin therapy and risks for death and hospitalization in chronic heart failure[J].JAMA.2006,296(17):2105-2111.
  • 10[9]Flevari P,Parissis JT,Leftheriotis D,et al.Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy[J].Am J Cardiol,2006,98(12):1641-1645.

共引文献72

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部